Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis

British Journal of Dermatology

Volumn 159, Issue 2, 2008, Pages 322-330

  Strober, B ^a   Teller, C ^b   Yamauchi, P ^c   Miller, J L ^d   Hooper, M ^e   Yang, Y C ^e   Dann, F ^f  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e AMGEN INC   (United States)

^f VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

C reactive protein; Cardiovascular disease; Inflammation; Obesity; Psoriasis; Psoriatic arthritis

Indexed keywords

C REACTIVE PROTEIN; ETANERCEPT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

ADULT; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT DURATION;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 47549084413     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08628.x     Document Type: Article

References (41)

1. Neimann AL, Shin DB, Wang X et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006 55 : 829 35.
2. Ludwig RJ, Herzog C, Rostock A et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007 156 : 271 6.
3. Gelfand JM, Gladman DD, Mease PJ et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005 53 : 573.
4. Mease P. Psoriatic arthritis update. Bull Hosp Jt Dis 2006 64 : 25 31.
5. Zachariae H, Zachariae R, Blomqvist K et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol (Stockh) 2002 82 : 108 13.
6. Green L, Meyers OL, Gordon W et al. Arthritis in psoriasis. Ann Rheum Dis 1981 40 : 366 9.
7. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007 445 : 866 73.
8. Nickoloff BJ. Cracking the cytokine code in psoriasis. Nat Med 2007 13 : 242 4.
9. Vandevoorde V, Haegeman G, Fiers W. TNF-mediated IL6 gene expression and cytotoxicity are co-inducible in TNF-resistant L929 cells. FEBS Lett 1992 302 : 235 8.
10. Toniatti C, Arcone R, Majello B et al. Regulation of the human C-reactive protein gene, a major marker of inflammation and cancer. Mol Biol Med 1990 7 : 199 212.
11. Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 2004 29 : 439 93.
12. ® (etanercept prescribing information). 2008. Manufactured by Immunex Corporation. Marketed by Amgen and Wyeth Pharmaceuticals.
13. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003 349 : 2014 22.
14. Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003 107 : 499 511.
15. World Health Organization. Global Database on Body Mass Index. BMI Classification. Available at: http://www.who.int/bmi/index.jsp?introPage= intro_3.html (last accessed 8 May 2008).
16. Mease PJ, Goffe BS, Metz J et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000 356 : 385 90.
17. Inoue N. Vascular C-reactive protein in the pathogenesis of coronary artery disease: role of vascular inflammation and oxidative stress. Cardiovasc Hematol Disord Drug Targets 2006 6 : 227 31.
18. Boekholdt SM, Hack CE, Sandhu MS et al. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. Atherosclerosis 2006 187 : 415 22.
19. Clearfield MB. C-reactive protein: a new risk assessment tool for cardiovascular disease. J Am Osteopath Assoc 2005 105 : 409 16.
20. Cushman M, Arnold AM, Psaty BM et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation 2005 112 : 25 31.
21. Ishikawa S, Kayaba K, Gotoh T et al. Metabolic syndrome and C-reactive protein in the general population: JMS Cohort Study. Circ J 2007 71 : 26 31.
22. Ridker PM, Buring JE, Cook NR et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003 107 : 391 7.
23. Bernstein LE, Berry J, Kim S et al. Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 2006 166 : 902 8.
24. Ridker PM, Cannon CP, Morrow D et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005 352 : 20 8.
25. Hak AE, Stehouwer CD, Bots ML et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 1999 19 : 1986 91.
26. Mora S, Lee IM, Buring JE et al. Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. JAMA 2006 295 : 1412 9.
27. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995 32 : 982 6.
28. Herron MD, Hinckley M, Hoffman MS et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005 141 : 1527 34.
29. Warnberg J, Nova E, Moreno LA et al. Inflammatory proteins are related to total and abdominal adiposity in a healthy adolescent population: the AVENA Study. Am J Clin Nutr 2006 84 : 505 12.
30. Gelfand JM, Neimann AL, Shin DB et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006 296 : 1735 41.
31. Ridker PM, Rifai N, Pfeffer MA et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999 100 : 230 5.
32. Albert MA, Danielson E, Rifai N et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001 286 : 64 70.
33. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001 103 : 1191 3.
34. Dixon WG, Watson KD, Lunt M et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007 56 : 2905 12.
35. Jacobsson LT, Turesson C, Gulfe A et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005 32 : 1213 8.
36. Huvers FC, Popa C, Netea MG et al. Improved insulin sensitivity by anti-TNFalpha antibody treatment in patients with rheumatic diseases. Ann Rheum Dis 2007 66 : 558 9.
37. Del Porto F, Laganà B, Lai S et al. Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. Rheumatology (Oxford) 2007 46 : 1111 5.
38. Popa C, Netea MG, Radstake T et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005 64 : 303 5.
39. Gonzalez-Juanatey C, Llorca J, Sanchez-Andrade A et al. Short-term adalimumab therapy improves endo-thelial function in patients with rheumatoid arthritis refractory to infliximab. Clin Exp Rheumatol 2006 24 : 309 12.
40. Prodanovich S, Ma F, Taylor JR et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005 52 : 262 7.
41. Choi HK, Hernan MA, Seeger JD et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002 359 : 1173 7.